Please assess the completion status of the following clinical trial:

Trial Title: SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The following are requirements for entry into the study. The subject MUST:~1. Be ≥ 18 years of age~2. Be diagnosed with a ventral hernia as defined as:~1. Midline Ventral Hernia AND~2. Defect(s) MUST meet the following criteria:~   * contained within an anatomical area of ≤ 150 cm2~  * not be longer than 8cm in any direction~  * size must have a total sum ≤ 64 cm2~3. Be eligible for retro-rectus placement of SERI~4. Have a BMI \< 40~Exclusion Criteria:~The following are criteria for exclusion from participating in the study. The subject must~NOT:~1. Be \> 70 years of age~2. Have prior occurrence of ventral hernia or parastomal hernia~3. Have a presence of a stoma or have a perforated bowel~4. Have any documented disease which is clinically known to impact wound healing, including Chronic Obstructive Pulmonary Disease (COPD), and Congestive Heart Failure (CHF), with the exception of controlled diabetes~5. Have documented history of diabetes with an A1C of ≥ 8 at time of pre-operative visit~6. Have documented autoimmune disease, an immune deficiency, or be on immunosuppressive drugs with the exception of steroids for:~1. prophylactic one-time-use administered peri-operatively~2. inhaled general use~3. topical administration~7. Have documented collagen-vascular, connective tissue, bleeding disorders and/or on anticoagulation therapy, with the exception of baby aspirin for one week prior to SERI placement~8. Have documented cancer \< 6 months prior to surgery or chemotherapy treatment \< 6 months prior to surgery~9. Have documented history of abdominal radiation therapy or is expected to have abdominal radiation therapy during the conduct of this study~10. Have documented history of liver disease and/or renal failure requiring dialysis~11. Have documented history of a previous wound infection at the surgical site or have an active infection at the time of surgery~12. Have had prior surgery with synthetic and/or biologic mesh in the abdominal, chest or pelvic area~13. Have documented allergy to silk~14. Have documented UTI at the time of surgery~15. Have smoked within 6 weeks of surgery and have a positive nicotine test at time of preoperative visit~16. Have a concurrent procedure intra-operatively (with the exception of lysis of abdominal adhesions)~17. Require intra-peritoneal or bridging placement of the soft tissue support device or require component separation at time of surgery~18. Have surgical circumstances that are contraindicated for use of SERI™ Surgical Scaffold per the supplied package insert~19. Have a concomitant unrelated condition of abdominal/chest wall/skin that would require a surgical intervention during the follow-up period~20. Have documented alcohol and/or substance abuse problem at time of pre-operative visit~21. Be pregnant, lactating, or if of childbearing potential, be unwilling to use contraceptive methods and avoid pregnancy throughout the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SERI® Surgical Scaffold (Type: EXPERIMENTAL): It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues